BioNTech Shifts Development Costs to Roche While Buying Regulatory Speed for $205 Million
Published on 11/13/2026 at 05:22 | Editorial boerse-global.de
BioNTech has moved on two fronts at once, reshaping who pays for its pipeline while paying up to move a late-stage oncology candidate through the U.S. approval process faster. The Mainz-based company said on 3 November it had exercised an option in its collaboration with Roche/Genentech, under which the partner will in principle fund research and development for the program going forward.
Under the arrangement, Roche/Genentech takes over future R&D costs from 1 January 2027, and BioNTech could receive licensing payments if development and commercialization succeed. The ongoing pancreatic cancer trial is to continue as planned. For investors, the question shifts from the next trial readout to who finances the path there — and how much of any eventual success stays with BioNTech.
A $205 Million Voucher and a Widening Legal Front
The same day, BioNTech agreed to buy an FDA Priority Review Voucher from Scholar Rock for $205 million in cash, payable in full, with the intention of using it for a future application from its advanced oncology pipeline. The transaction is subject to customary conditions, including HSR clearance.
Should investors sell immediately? Or is it worth buying BioNTech?
On the legal side, Arbutus Biopharma and Genevant expanded their Canadian patent suit against Pfizer and BioNTech with a newly granted LNP patent, seeking financial compensation and injunctions. The plaintiffs also filed two patent lawsuits in Japan against Pfizer Japan, while BioNTech is named as a defendant in the expanded Canadian case.
Third-Quarter Numbers and a Raised Outlook
The financial backdrop came with last week's results: revenue of €1.2892 billion for the third quarter of 2026 and net profit of €184.5 million. As of 30 September, BioNTech held cash, cash equivalents and securities of €16.2 billion. The company also raised its 2026 revenue guidance from €1.6–1.9 billion to €1.7–1.9 billion.
Media reports on Tuesday said around 40 jobs are to be cut after failed negotiations, mainly in Mainz as well as in Berlin and Munich, following earlier low-three-digit cuts at the Mainz site, particularly in IT. Shares showed a daily move of -2.7% on Thursday.
What ties the strands together is the financing of the road from development to possible commercialization. BioNTech is deploying capital for a later filing while shifting future program costs to a partner — a combination whose value depends on the voucher purchase closing and the partnered program advancing.
Ad
BioNTech Stock: New Analysis - 13 November
Fresh BioNTech information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
